Novartis moves into a "new growth cycle"
This article was originally published in Scrip
Novartisis expecting its pharmaceuticals business to accelerate in the fourth quarter, when net sales should increase at a high-single digit rate, in local currencies. This is better news than expected, because lower growth had previously been forecast, commented chairman CEO Daniel Vasella.
You may also be interested in...
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.